symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ENLV,1.4,0.711002,25362,26038040,0,1.31-4.92,0.004,Enlivex Therapeutics Ltd.,USD,0001596812,IL0011319527,M4130Y106,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.enlivex.com,"Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",Mr. Shai  Novik M.B.A.,Healthcare,IL,71,972 8 662 3301,14 Einstein Street,Ness Ziona,,7403618,1.06062,5.48062,https://financialmodelingprep.com/image-stock/ENLV.png,2014-07-31,False,False,True,False,False
